print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
17/11/2016 (Added to site)
Author(s): Yu, Z.; Yan, B.; Gao, L.; Dong, C.; Zhong, J. D.; Ortenzio, M.; Nguyen, B.; Seong Lee, S.; Hu, X.; Liang, F.

Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review

Journal: Current Cancer Drug Targets, 16/6 (2016), pp. 509-521
DOI: n/a
Request reprint  |  Tell your friend  | 

Abstract: Despite being one of the most effective broad-spectrum chemotherapeutic agents in the treatment of cancers, the clinical applications of bleomycins (BLMs) have been limited due to their poor drug delivery abilities, and the side effect of causing lung fibrosis. With the increased therapeutics and the reduction of side effects, research and development of targeted drug delivery systems (TDDS) with BLMs have become essential for the expansive clinical usage of BLM-based therapeutics. This review summarizes the recent developments of various TDDS for BLMs, including techniques such as photochemical internalization, ultrasound, and micelle, liposome, and nanoparticle formation. The advantages and disadvantages for each delivery approach are outlined, along with the specific challenges associated with each delivery system.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: